Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 1997

View Archived Issues

Initial phase III results announced for pramlintide

CardioSynopsis, IHIM to co-develop novel stents

IND filed by Dusa for Levulan photodetection

Positive phase III results for Lidakol in oral herpes

Chiron Diagnostics launches breast cancer test

Alaris enters marketing agreement with Luther Medical

Three patents issued for ProLease and Medisorb

Alkermes and Janssen sign supply agreement

Generic Cardizem CD open for FDA review

Preclinical results on AVI-2221 for restenosis

Penederm launches Avita acne cream

Infanrix Hep B approved in all EU countries

ETA/ETB antagonist protects against renal insufficiency in canine model

Novopharm Biotech antibodies poised to enter phase I

Optison evaluated in phase II trials for myocardial perfusion imaging

Trega Biosciences refocuses development of HP-228

Analgesic mGluR antagonists reported in patent literature

Novel immunotoxins for the treatment of AIDS

Clobenpropit shows memory-enhancing activity in preclinical models

Tachykinin antagonist with potential as antiasthmatic

Efficacy of long-term treatment with dronabinol for AIDS-related anorexia

Antidepressant activity described for 5-HT reuptake inhibitor/5-HT antagonist

Bristol-Myers Squibb describes new taxanes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...